Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Abstract EN

Background.

Cardiac contractility modulation (CCM) is a device therapy for systolic heart failure (HF) in patients with narrow QRS.

We aimed to perform an updated meta-analysis of the randomized clinical trials (RCTs) to assess the efficacy and safety of CCM therapy.

Methods.

We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) between January 2001 and June 2018.

Outcomes of interest were peak oxygen consumption (peak VO2), 6-Minute Walk Distance (6MWD), Minnesota Living with Heart Failure Questionnaire (MLHFQ), HF hospitalizations, cardiac arrhythmias, pacemaker/ICD malfunctioning, all-cause hospitalizations, and mortality.

Data were expressed as standardized mean difference (SMD) or odds ratio (OR).

Results.

Four RCTs including 801 patients (CCM n = 394) were available for analysis.

The mean age was 59.63 ± 0.84 years, mean ejection fraction was 29.14 ± 1.22%, and mean QRS duration was 106.23 ± 1.65 msec.

Mean follow-up duration was six months.

CCM was associated with improved MLWHFQ (SMD -0.69, p = 0.0008).

There were no differences in HF hospitalizations (OR 0.76, p = 0.12), 6MWD (SMD 0.67, p = 0.10), arrhythmias (OR 1.40, p = 0.14), pacemaker/ICD malfunction/sensing defect (OR 2.23, p = 0.06), all-cause hospitalizations (OR 0.73, p = 0.33), or all-cause mortality (OR 1.04, p = 0.92) between the CCM and non-CCM groups.

Conclusions.

Short-term treatment with CCM may improve MLFHQ without significant difference in 6MWD, arrhythmic events, HF hospitalizations, all-cause hospitalizations, and all-cause mortality.

There is a trend towards increased pacemaker/ICD device malfunction.

Larger RCTs might be needed to determine if the CCM therapy will be beneficial with longer follow-up.